Bezafibrate Improves Postprandial Hypertriglyceridemia and Associated Endothelial Dysfunction in Patients with Metabolic Syndrome: a Randomized Crossover Study

Overview

Journal Cardiovasc Diabetol

Publisher Biomed Central

Specialties Cardiology & Vascular Diseases
Endocrinology

Date 2014 Apr 9

PMID 24708775

Citations 14

Authors

Yuko Ohno

Toru Miyoshi

Yoko Noda

Hiroki Oe

Norihisa Toh

Kazufumi Nakamura

Kunihisa Kohno

Hiroshi Morita

Hiroshi Ito

Affiliations

Soon will be listed here.

Abstract

Background: Postprandial elevation of triglyceride-rich lipoproteins impairs endothelial function, which can initiate atherosclerosis. We investigated the effects of bezafibrate on postprandial endothelial dysfunction and lipid profiles in patients with metabolic syndrome.

Methods: Ten patients with metabolic syndrome were treated with 400 mg/day bezafibrate or untreated for 4 weeks in a randomized crossover study. Brachial artery flow-mediated dilation (FMD) and lipid profiles were assessed during fasting and after consumption of a standardized snack. Serum triglyceride and cholesterol contents of lipoprotein fractions were analyzed by high-performance liquid chromatography.

Results: Postprandial FMD decreased significantly and reached its lowest value 4 h after the cookie test in both the bezafibrate and control groups, but the relative change in FMD from baseline to minimum in the bezafibrate group was significantly smaller than that in the control group (-29.0 ± 5.9 vs. -42.9 ± 6.2%, p = 0.04). Bezafibrate significantly suppressed postprandial elevation of triglyceride (incremental area under the curve (AUC): 544 ± 65 vs. 1158 ± 283 mg h/dl, p = 0.02) and remnant lipoprotein cholesterol (incremental AUC: 27.9 ± 3.5 vs. 72.3 ± 14.1 mg h/dl, p < 0.01). High-performance liquid chromatography analysis revealed that postprandial triglyceride content of the chylomicron and very low-density lipoprotein fractions was significantly lower in the bezafibrate group than in the control group (p < 0.05).

Conclusion: Bezafibrate significantly decreased postprandial endothelial dysfunction, and elevations of both exogenous and endogenous triglycerides in patients with metabolic syndrome, suggesting that bezafibrate may have vascular protective effects in these patients.

Clinical Trial Registration: Unique Identifiers: UMIN000012557.

Citing Articles

Japan Atherosclerosis Society (JAS) Guidelines for Prevention of Atherosclerotic Cardiovascular Diseases 2022.

Okamura T, Tsukamoto K, Arai H, Fujioka Y, Ishigaki Y, Koba S J Atheroscler Thromb. 2023; 31(6):641-853.

PMID: 38123343 PMC: 11150976. DOI: 10.5551/jat.GL2022.

The Role of Triglyceride-rich Lipoproteins and Their Remnants in Atherosclerotic Cardiovascular Disease.

Gabani M, Shapiro M, Toth P Eur Cardiol. 2023; 18:e56.

PMID: 37860700 PMC: 10583159. DOI: 10.15420/ecr.2023.16.

Postprandial Hyperlipidemia: Its Pathophysiology, Diagnosis, Atherogenesis, and Treatments.

Yanai H, Adachi H, Hakoshima M, Katsuyama H Int J Mol Sci. 2023; 24(18).

PMID: 37762244 PMC: 10530470. DOI: 10.3390/ijms241813942.

Association between High Pericoronary Adipose Tissue Computed Tomography Attenuation and Impaired Flow-Mediated Dilation of the Brachial Artery.

Ichikawa K, Miyoshi T, Ohno Y, Osawa K, Nakashima M, Nishihara T J Atheroscler Thromb. 2022; 30(4):364-376.

PMID: 35753780 PMC: 10067336. DOI: 10.5551/jat.63580.

A single, high-fat meal adversely affects postprandial endothelial function: a systematic review and meta-analysis.

Fewkes J, Kellow N, Cowan S, Williamson G, Dordevic A Am J Clin Nutr. 2022; 116(3):699-729.

PMID: 35665799 PMC: 9437993. DOI: 10.1093/ajcn/nqac153.

References

Nordestgaard B, Benn M, Schnohr P, Tybjaerg-Hansen A . Nonfasting triglycerides and risk of myocardial infarction, ischemic heart disease, and death in men and women. JAMA. 2007; 298(3):299-308. DOI: 10.1001/jama.298.3.299. View

Corretti M, Anderson T, Benjamin E, Celermajer D, Charbonneau F, Creager M . Guidelines for the ultrasound assessment of endothelial-dependent flow-mediated vasodilation of the brachial artery: a report of the International Brachial Artery Reactivity Task Force. J Am Coll Cardiol. 2002; 39(2):257-65. DOI: 10.1016/s0735-1097(01)01746-6. View

Nakamura T, Takano H, Umetani K, Kawabata K, Obata J, Kitta Y . Remnant lipoproteinemia is a risk factor for endothelial vasomotor dysfunction and coronary artery disease in metabolic syndrome. Atherosclerosis. 2005; 181(2):321-7. DOI: 10.1016/j.atherosclerosis.2005.01.012. View

Sandoval J, Nakagawa-Toyama Y, Masuda D, Tochino Y, Nakaoka H, Kawase R . Fenofibrate reduces postprandial hypertriglyceridemia in CD36 knockout mice. J Atheroscler Thromb. 2010; 17(6):610-8. DOI: 10.5551/jat.3988. View

Usui S, Hara Y, Hosaki S, Okazaki M . A new on-line dual enzymatic method for simultaneous quantification of cholesterol and triglycerides in lipoproteins by HPLC. J Lipid Res. 2002; 43(5):805-14. View

Bansal S, Buring J, Rifai N, Mora S, Sacks F, Ridker P . Fasting compared with nonfasting triglycerides and risk of cardiovascular events in women. JAMA. 2007; 298(3):309-16. DOI: 10.1001/jama.298.3.309. View

Cannon C, Steinberg B, Murphy S, Mega J, Braunwald E . Meta-analysis of cardiovascular outcomes trials comparing intensive versus moderate statin therapy. J Am Coll Cardiol. 2006; 48(3):438-45. DOI: 10.1016/j.jacc.2006.04.070. View

Botham K, Wheeler-Jones C . Postprandial lipoproteins and the molecular regulation of vascular homeostasis. Prog Lipid Res. 2013; 52(4):446-64. DOI: 10.1016/j.plipres.2013.06.001. View

Pauciullo P, Borgnino C, Paoletti R, Mariani M, Mancini M . Efficacy and safety of a combination of fluvastatin and bezafibrate in patients with mixed hyperlipidaemia (FACT study). Atherosclerosis. 2000; 150(2):429-36. DOI: 10.1016/s0021-9150(00)00379-8. View

10.

Norata G, Grigore L, Raselli S, Redaelli L, Hamsten A, Maggi F . Post-prandial endothelial dysfunction in hypertriglyceridemic subjects: molecular mechanisms and gene expression studies. Atherosclerosis. 2006; 193(2):321-7. DOI: 10.1016/j.atherosclerosis.2006.09.015. View

11.

Attia N, Durlach V, Cambilleau M, Roche D, Girard-Globa A . Postprandial concentrations and distribution of apo C-III in type 2 diabetic patients. Effect Of bezafibrate treatment. Atherosclerosis. 2000; 149(2):427-33. DOI: 10.1016/s0021-9150(99)00337-8. View

12.

Teramoto T, Shirai K, Daida H, Yamada N . Effects of bezafibrate on lipid and glucose metabolism in dyslipidemic patients with diabetes: the J-BENEFIT study. Cardiovasc Diabetol. 2012; 11:29. PMC: 3342914. DOI: 10.1186/1475-2840-11-29. View

13.

Wang Y, Yang Q, Yan J, Zhao C, Cianflone K, Wang D . Effects of bezafibrate on the expression of endothelial nitric oxide synthase gene and its mechanisms in cultured bovine endothelial cells. Atherosclerosis. 2005; 187(2):265-73. DOI: 10.1016/j.atherosclerosis.2005.09.008. View

14.

Olijhoek J, Hajer G, van der Graaf Y, Dallinga-Thie G, Visseren F . The effects of low-dose simvastatin and ezetimibe compared to high-dose simvastatin alone on post-fat load endothelial function in patients with metabolic syndrome: a randomized double-blind crossover trial. J Cardiovasc Pharmacol. 2008; 52(2):145-50. DOI: 10.1097/FJC.0b013e31817ffe76. View

15.

Rosenson R, Wolff D, Huskin A, Helenowski I, Rademaker A . Fenofibrate therapy ameliorates fasting and postprandial lipoproteinemia, oxidative stress, and the inflammatory response in subjects with hypertriglyceridemia and the metabolic syndrome. Diabetes Care. 2007; 30(8):1945-51. DOI: 10.2337/dc07-0015. View

16.

Tenenbaum A, Motro M, Fisman E, Schwammenthal E, Adler Y, Goldenberg I . Peroxisome proliferator-activated receptor ligand bezafibrate for prevention of type 2 diabetes mellitus in patients with coronary artery disease. Circulation. 2004; 109(18):2197-202. DOI: 10.1161/01.CIR.0000126824.12785.B6. View

17.

Tenenbaum A, Motro M, Fisman E, Adler Y, Shemesh J, Tanne D . Effect of bezafibrate on incidence of type 2 diabetes mellitus in obese patients. Eur Heart J. 2005; 26(19):2032-8. DOI: 10.1093/eurheartj/ehi310. View

18.

van Oostrom A, Sijmonsma T, Verseyden C, Jansen E, de Koning E, Rabelink T . Postprandial recruitment of neutrophils may contribute to endothelial dysfunction. J Lipid Res. 2003; 44(3):576-83. DOI: 10.1194/jlr.M200419-JLR200. View

19.

Murakami H, Murakami R, Kambe F, Cao X, Takahashi R, Asai T . Fenofibrate activates AMPK and increases eNOS phosphorylation in HUVEC. Biochem Biophys Res Commun. 2006; 341(4):973-8. DOI: 10.1016/j.bbrc.2006.01.052. View

20.

Suzuki S, Takeishi Y, Niizeki T, Koyama Y, Kitahara T, Sasaki T . Pentraxin 3, a new marker for vascular inflammation, predicts adverse clinical outcomes in patients with heart failure. Am Heart J. 2007; 155(1):75-81. DOI: 10.1016/j.ahj.2007.08.013. View